Compare Emerson Electric Co. (EMR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Enveric Biosciences Inc — how do they compare? Emerson Electric Co. trades at $160 (market cap $88.72B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: Emerson Electric Co. is far larger — about 13047.1× Enveric Biosciences Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Enveric Biosciences Inc for 14 Days on average.
| EMR | ENVB | |
|---|---|---|
Market Cap | $88.72B | $6.80M |
Volume | 2,355,255 | 64,867 |
Sector | Industrials | Health |
52-Week High | $164.38 | $10.80 |
52-Week Low | $123.30 | $1.27 |
Typical Hold Time | 81 Days | 14 Days |
Enterprise Value | $99.80B | -$1.49M |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% on the day, near its pivot point of $159. The stock shows a bullish technical trend with moving averages supporting upside momentum. Fundamentally, EMR delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected to reach $18.6B in 2026, while profitability remains solid with a net income margin of 13.83% in 2025.
The outlook for EMR is positive, supported by analyst consensus favoring a Buy rating (53.49%) and a $165.90 price target implying ~4% upside. Key risks include volatile cash flows, with net cash flow negative in 2025, and elevated debt levels. Investor sentiment is bolstered by strong institutional coverage and recent dividend declarations, though macroeconomic pressures on industrials warrant caution.
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
